VTGN — Vistagen Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1411685 ·
Last close
$0.19
Market Cap
$8.34M
52W High
$5.14
52W Low
$0.16
ADV30
768,455
Next earnings
2027-02-11
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 138,000 — -10,937,000 -10,740,000 23,421,000 10,892,000 8,429,000
Jun 2026 1,476,000 — -13,348,000 -13,030,000 35,736,000 16,991,000 11,255,000
Mar 2026 465,000 — -16,717,000 -16,274,000 48,564,000 30,789,000 13,044,000
Dec 2025 303,000 — -19,546,000 -18,899,000 65,056,000 47,371,000 14,136,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-62,297,000
Investing CF
$-89,000
Financing CF
$30,392,000
CapEx
$-239,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.76
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-490,347,000
Inventory
—
Receivables
—
ST Investments
$14,739,000
EBIT TTM
$-69,664,000
Pretax Income TTM
$-67,613,000
Interest Exp TTM
—
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,501,000
EBITDA
$-69,459,000
Free Cash Flow
$-36,950,752
Enterprise Value
$-22,936,968
Total Cash
$31,730,000
Total Debt
$783,000
Shares Out
44,376,911
Trailing EPS
$-1.66
Book Value
$0.55
ROE
-166.5%
ROA
-83.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2026 1,269,000 -72,126,000 -69,685,000 48,564,000 13,044,000 35,520,000 -66,436,000
Mar 2025 486,000 -55,973,000 -51,418,000 84,341,000 13,951,000 70,390,000 -42,097,000
Mar 2024 1,064,000 -33,021,000 -29,362,000 123,653,000 9,367,000 114,286,000 -25,813,000
Mar 2023 -227,000 -59,268,000 -59,248,000 21,089,000 9,009,000 12,080,000 -49,716,000

TTM Snapshot

Revenues TTM
$2,501,000
NetIncome TTM
$-67,620,000
OpCashFlow TTM
—
Assets (Latest)
$35,736,000
Forward EPS
$-1.54

Peers — same industry

TickerNameMarket CapLastDaily %
CALC CalciMedica, Inc. $8.41M $1.22 —
KYNB KYNTRA BIO, INC. $8.26M $2.04 —
DARE Dare Bioscience, Inc. $8.44M $0.43 —
MTVA MetaVia Inc. $8.24M $1.25 —
AEMD AETHLON MEDICAL INC $8.17M $5.08 —

News headlines (Yahoo Finance, 1h cache)

Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update
2026-11-13 21:05 · Yahoo
Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder
2026-11-09 13:30 · Yahoo
Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
2026-10-20 12:30 · Yahoo
2 Falling Stocks Call Traders Are Targeting Today
2026-09-25 14:50 · Yahoo
Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder
2026-09-24 13:58 · Yahoo
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
2026-09-24 11:00 · Yahoo
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
2026-09-22 12:30 · Yahoo
Vistagen to Present at Psych Congress 2026
2026-09-10 12:30 · Yahoo
SRX Global Acquires Stake in Vistagen Therapeutics
2026-08-04 15:35 · Yahoo
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
2026-08-04 09:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.